Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Postmarketing observational study of ARIA safety and management in early Alzheimer's disease patients treated with lecanemab (Japan)
jRCT2031240092Recruiting
- Sponsor
- Eisai Co., Ltd.
- Start
- Feb 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of lecanemab in Alzheimer's disease (AD), sponsored by Eisai Co., Ltd. Primary endpoints: Number of participants with ARIA-E and ARIA-H and Number of participants with interruption or discontinuation of lecanemab after onset of ARIA. Started Feb 2024; status: recruiting.
02
Drugs
lecanemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2031240092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240092.